David I. Quinn, MBBS, PhD, on Urothelial Cancer: Results from KEYNOTE-045
2017 ASCO Annual Meeting
David I. Quinn, MBBS, PhD, of the University of Southern California, gives his expert perspective on the planned survival analysis from a phase III open-label study of pembrolizumab vs paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer. (Abstract 4501)
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Clifford A. Hudis, MD, ASCO’s current CEO, discuss the state of cancer care and the challenges that lie ahead.
Peter Hoskin, MD, of Mount Vernon Cancer Centre, discusses study findings on single-dose radiotherapy compared with multifraction radiotherapy in patients with metastatic spinal canal compression. (Abstract LBA10004)
Solange Peters, MD, PhD, of the University of Lausanne, examines the study findings on nivolumab ± ipilimumab in advanced small cell lung cancer, in the first report of a randomized expansion cohort. (Abstract 8503)
Gunter von Minckwitz, MD, of the German Breast Group, discusses study findings on a randomized comparison of chemotherapy, trastuzumab, and placebo vs chemotherapy, trastuzumab, and pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer. (Abstract LBA500)
Temidayo Fadelu, MD, of Dana-Farber Cancer Institute, discusses study findings on nut consumption and survival in stage III colon cancer patients. Higher consumption of nuts may be associated with significantly reduced cancer recurrence and death in this group. (Abstract 3517)